重组人生长激素治疗特发性矮小51例疗效及安全性研究  

Study on The Efficacy and Safety of Recombinant Human Growth Hormone in The Treatment of Idiopathic Short Stature in 51 Cases

作　　者：呼双琴[1] 

机构地区：[1]延安大学附属医院,陕西延安716000

出　　处：《中国药业》2015年第17期5-7,共3页China Pharmaceuticals

摘　　要：目的探讨重组人生长激素治疗儿童特发性矮小的临床疗效及安全性。方法选择2012年1月至2013年8月医院收治的特发性矮小症患儿102例,随机分为对照组和观察组,各51例。两组患儿均予改善生活习惯、加强营养物质摄入等对症治疗,对照组加用生长胶囊,观察组加用重组人生长激素治疗。结果治疗后,观察组患儿的身高和生长速率均显著高于对照组(P<0.05)。治疗后两组患儿骨龄变化均属于生理增长范围,组间无明显差异(P>0.05)。观察组患儿的年龄身高标准差积分和骨龄身高标准差积分均显著改善(P<0.05),对照组无显著改善(P>0.05)。两组患者不良反应发生率无显著性差异(P>0.05)。结论重组人生长激素治疗特发性矮小疗效确切,过程安全,同时不会造成骨龄的增长加速。Objective To investigate the efficacy of recombinant human growth hormone in the treatment of idioPathic short stature in children and to evaluate its safety. Methods 102 children with idioPathic short stature from January 2012 to August 2013 in the hos-Pital were selected and randomly divided into the control grouP and the observation grouP, 51 cases in each grouP. The two grouPs were given symPtomatic treatment;the control grouP was added with Shengzhang CaPsules, and the observation grouP was added with recombi-nant human growth hormone. Results After treatment, the height and growth rate of the observation grouP were significantly higher than those of the control grouP （ P 〈 0. 05 ） . Changes of bone age growth in the two grouPs belonged to the normal Physiological range, and with no significant difference between the two grouPs （ P 〉 0. 05 ） . The age, height and standard deviation score and bone age height standard deviation score of the observation grouP imProved significantly （ P 〈 0. 05 ） , and the control grouP had no obvious imProvement （ P 〉 0. 05）. There was no significant difference between the two grouPs in drug related adverse reactions（ P 〉 0. 05）. Conclusion The efficacy of recombinant human growth hormone in treating idioPathic short stature is exact with safe Process, and without the acceleration of bone growth.

关 键 词：重组人生长激素 特发性矮小 临床疗效 生长速率 骨龄 

分 类 号：R969.4[医药卫生—药理学] R977.1[医药卫生—药学]